Scientists at the University of Pennsylvania have made a significant breakthrough in treating aggressive brain cancer by developing an innovative CAR-T immunotherapy. This treatment targets two tumor proteins simultaneously – EGFR and IL13Rα2 – and has shown impressive results in clinical trials.
Researchers introduced modified cells directly into the cerebrospinal fluid, significantly increasing treatment effectiveness. In a trial involving 18 patients with recurrent glioblastoma, 62% showed significant tumor size reduction. The survival rate was also impressive, with 43% of participants surpassing the one-year mark after treatment.
One patient has remained stable for 16 months, demonstrating the long-term efficacy of this therapy. While neurological side effects were common, they were successfully controlled in all patients.
The researchers plan to test multiple administrations and apply their method to patients with primary diagnosis. Further improvements are expected to enhance this promising technology. This breakthrough offers new hope for those struggling with aggressive brain cancer.
Source: https://baku.ws/en/this-is-interesting/scientists-achieve-breakthrough-in-treating-aggressive-brain-cancer